Back to search
Pulmonary Alveolar Proteinosis
Clinical trial pipeline · Data from ClinicalTrials.gov
See which Pulmonary Alveolar Proteinosis trials you may qualify forClinical trial pipeline · Data from ClinicalTrials.gov
See which Pulmonary Alveolar Proteinosis trials you may qualify forThe major goal of Part A of this study is to establish a National PAP Registry to help make reliable new research tests available to doctors to improve the diag…
The goal of this open-label study is to study molgramostim as a treatment for autoimmune pulmonary alveolar proteinosis (aPAP) in pediatric patients between age…
The major goal of this study is to evaluate a new type of cell transplantation therapy for individuals with hereditary PAP, study a new treatment that may be us…
Generation of a common European database and biobank Continous assessment and implementation of guidelines and treatment protocols Establishment of a large obse…
Background: * Healthy people have white blood cells that protect them against bacteria, viruses, and fungi. However, some people have diseases which cause the…
Mutations in the MARS gene encoding methionyl-tRNA synthetase are responsible for a genetic form of alveolar proteinosis (PAP), but the pathophysiological mecha…
Autoimmune pulmonary alveolar proteinosis (aPAP) is a rare disorder in which a material called surfactant builds up in the lungs and makes it hard to breathe. I…